American College of Cardiology 2022 Meeting Topics Feature Novel Therapies, Updates in Heart Failure

Pharmacy Times will be covering the American College of Cardiology (ACC) 2022 meeting live in Washington, DC, from April 2 through 4, 2022.

Themes for the conference include the latest updates in cardiovascular care, novel therapeutics, and innovative changes in practice. During the meeting, the 53rd annual Louis F. Bishop Keynote address will be delivered by Dariush Mozaffarian, MD, DrPh, who will discuss how clinicians can advise their patients on heart-healthy dietary choices. The Eugene Braunwald Keynote, delivered by Peter Libby, MD, FACC, will discuss the link between inflammation and atherosclerosis.

Other key sessions to watch for include coverage of obesity management, social determinants of health, and equity in cardiovascular care.

  • On April 2, a session titled “Stroke Prevention in Atrial Fibrillation” will cover techniques to improve patient anticoagulation therapy compliance. Despite the demonstrated efficacy of anticoagulation therapies, ensuring compliance can still be a challenge. In the session, experts will address issues such as underrecognized risk factors for stroke, community screening for atrial fibrillation, and barriers to compliance.
  • On April 3, a group of experts will discuss how social determinants of health can be incorporated into the daily care of patients with ischemic heart disease. The session will cover how to identify social determinants of health in patients before turning to the negative impacts social determinants of health can have for patients with ischemic heart disease. Finally, the panelists will review ways to mitigate those impacts for patients.
  • A session titled “Trends and Updates in PAD” will review the latest medical therapy and guideline updates for peripheral arterial disease (PAD). Speakers will also cover available therapies for femoropopliteal segment, a patient-level safety update, the use of intravascular ultrasound in PAD, and the radial approach to treatment.
  • In Pharmacology Session 1, clinicians will review anticoagulation and device management strategies in mechanical circulatory support. Panelists will describe efficacy data and experiences using unfractionated heparin compared with a direct thrombin inhibitor, and will review the various anticoagulation monitoring parameters currently utilized.
  • Finally, a scientific session on Monday will discuss persistent cardiopulmonary limitations for patients who had COVID-19, including current knowledge about the post-acute COVID-19 syndrome. Speakers will address whether COVID-19 itself causes long-term cardiomyopathy as well as how to identify cases in which the disease uncovered other underlying cardiopulmonary issues.

Stay tuned for Pharmacy Times’ coverage throughout the conference, including session recaps and interviews with experts.